Seven years running a publicly-traded biotech are likely to give anyone a sense of the manic nature and the volatile ups and downs of drug development. And Mike Weiss, who headed Keryx Pharmaceuticals (NASDAQ: KERX) from 2002 to 2009, has... Read more »
Drug development is a tough business. Small companies that dare to try often end up in public train wrecks when they head to Washington to meet the FDA. It’s a shame, a colossal waste, every time a company gets that far... Read more »
Consumer Reports, the nation’s most respected source of product reviews and buying advice, does not mince words about extended warranties. It calls them a bad idea and money down the drain. The website Consumerist agrees, calling extended warranties useless... Read more »
The big news here at Xconomy this week was the launch of our new Texas bureau. But out on the East Coast, the life sciences industry was buzzing from top to bottom as well. Nine-figure partnerships, FDA advisory panel debacles,... Read more »
Trumpeting the upcoming debut of the Optimus G Pro phablet, last night LG Electronics brought the press, analysts, and other guests to the Metropolitan Pavilion in New York to check out the device. With dusky lighting and indie rock band Atlas... Read more »
Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says today it has agreed to work with Merck (NYSE: MRK) on a drug development... Read more »
Diversifying what is considered the face of technology could encourage more women to become founders, says Kathryn Minshew, CEO and co-founder of New York career advice site The Muse and sister news site The Daily Muse.
She chatted with me after... Read more »